Etelcalcetide: Physiology and What Research Reports

What etelcalcetide is

Etelcalcetide is a synthetic peptide calcimimetic — a molecule that makes the calcium-sensing receptor (CaSR) behave as though extracellular calcium were higher than it actually is. A first global approval summary described etelcalcetide as a peptide agonist of the calcium-sensing receptor developed for intravenous administration in patients with secondary hyperparathyroidism on hemodialysis (PMID 27900648). Unlike parathyroid hormone, calcitonin or the incretins, etelcalcetide is not a hormone that any human tissue secretes; it is a manufactured peptide, so a physiology entry for it describes a receptor target rather than an endogenous production site. A formulary review described the agent as administered intravenously at the end of hemodialysis sessions three times weekly (PMID 29276237).

The physiology it acts on

The calcium-sensing receptor sits on the surface of parathyroid chief cells and continuously samples extracellular ionised calcium. When calcium falls, receptor signalling drops and parathyroid hormone (PTH) secretion rises; when calcium rises, the receptor suppresses PTH release. In advanced kidney disease this loop is disturbed: phosphate retention, reduced active vitamin D and parathyroid hyperplasia drive persistently high PTH, the state called secondary hyperparathyroidism. Reviews of hyperparathyroidism management in hemodialysis described calcimimetics as agents that act on this receptor to lower PTH, in contrast with vitamin D receptor activators (PMID 29440923).

How it differs from the oral calcimimetic

A comparative review examined how cinacalcet and etelcalcetide differ, describing distinct interactions with the calcium-sensing receptor as well as differences in route of administration and elimination between the oral small molecule and the intravenous peptide (PMID 30009474). An expert pharmacotherapy review similarly framed etelcalcetide as a parenteral option intended for use during dialysis sessions in secondary hyperparathyroidism (PMID 28277829).

How it is measured and studied

Studies of etelcalcetide are built around laboratory endpoints rather than symptom scales. The usual measurements described in this literature include:

• Serum PTH — the primary endpoint in the head-to-head randomised trial of etelcalcetide versus cinacalcet in hemodialysis patients with secondary hyperparathyroidism (PMID 28097356).
• Serum calcium and phosphate — tracked as both efficacy and safety measures in reviews of the drug's clinical utility (PMID 28615947).
• Bone histomorphometry and bone quality indices — assessed in a study of changes in bone quality after treatment with etelcalcetide (PMID 37574661).
• Cardiac imaging — left ventricular hypertrophy was the focus of a commentary on lessons from the effect of etelcalcetide on left ventricular mass in end-stage kidney disease (PMID 35703173).

What the literature reports

Parathyroid hormone

The best-known comparison is a randomised clinical trial published in JAMA in which researchers compared intravenous etelcalcetide with oral cinacalcet in patients receiving hemodialysis with secondary hyperparathyroidism and reported that a greater proportion of participants achieved a reduction in serum PTH of more than 30% with etelcalcetide over the trial period (PMID 28097356). Narrative reviews of the agent's clinical utility summarised the trial programme as showing consistent PTH lowering in dialysis populations (PMID 28615947).

Bone

A CJASN study examined changes in bone quality after treatment with etelcalcetide in hemodialysis patients and reported alterations in bone turnover and related histological measures following treatment (PMID 37574661). A separate review of the impact of cinacalcet and etelcalcetide on bone mineral and cardiovascular disease in dialysis patients discussed how PTH lowering with calcimimetics relates to skeletal and vascular outcomes (PMID 36848027).

Heart

A commentary in Current Opinion in Nephrology and Hypertension discussed the effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease and what those findings imply for interpreting surrogate cardiac endpoints (PMID 35703173).

Switching between calcimimetics

A 2025 report in Clinical Nephrology examined the effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism, describing changes in mineral-metabolism parameters after the change in agent (PMID 40833047).

Specific populations

A theoretical overview considered clinical and pharmacological aspects of etelcalcetide use in diabetic patients undergoing hemodialysis, a group in which mineral metabolism and vascular calcification are often more advanced (PMID 29719376).

Adverse events: what studies report

Because etelcalcetide lowers PTH by activating the calcium-sensing receptor, the events most often described in the literature follow directly from that mechanism. In the randomised comparison with cinacalcet, researchers reported hypocalcaemia-related events as well as gastrointestinal symptoms such as nausea and vomiting among the adverse events recorded in both treatment groups (PMID 28097356). A formulary drug review summarised decreases in serum calcium as a principal safety consideration described in the etelcalcetide programme (PMID 29276237), and a review of hyperparathyroidism management in hemodialysis discussed monitoring of calcium during calcimimetic therapy (PMID 29440923). Reviews of the agent's clinical utility also noted that oversuppression of PTH is a theoretical concern for bone in dialysis patients (PMID 28615947).

Why the term matters to peptide readers

Etelcalcetide is a useful example for anyone reading peptide literature because it shows that "peptide" describes chemistry, not a regulatory category. It is a prescription medicine reviewed and approved through conventional regulatory channels, as described in its first global approval summary (PMID 27900648), and it is administered inside a dialysis unit under clinical monitoring rather than studied as a general-purpose research peptide. It also illustrates receptor pharmacology that recurs across peptide science: an allosteric or orthosteric agonist can amplify an existing physiological signal — here, the calcium-sensing loop — with the predictable consequence that the same mechanism producing the benefit also produces the main laboratory risk.

Limits of the evidence

The cited literature is concentrated in hemodialysis populations with secondary hyperparathyroidism, and much of it consists of narrative reviews rather than new trial data (PMID 28277829). Endpoints are largely biochemical and imaging-based; reviews of bone and cardiovascular outcomes with calcimimetics noted that linking PTH lowering to hard clinical outcomes remains a matter of interpretation (PMID 36848027). Nothing in this literature addresses use outside kidney disease. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or laboratory result.

References

• Etelcalcetide: First Global Approval (Drugs, 2016)
• Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial (JAMA, 2017)
• Formulary Drug Review: Etelcalcetide (Hospital Pharmacy, 2017)
• Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide (Therapeutics and Clinical Risk Management, 2017)
• Etelcalcetide for the treatment of secondary hyperparathyroidism (Expert Opinion on Pharmacotherapy, 2017)
• Managing hyperparathyroidism in hemodialysis: role of etelcalcetide (International Journal of Nephrology and Renovascular Disease, 2018)
• Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? (Seminars in Dialysis, 2018)
• Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis (Drug Design, Development and Therapy, 2018)
• Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease (Current Opinion in Nephrology and Hypertension, 2022)
• Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients (Current Osteoporosis Reports, 2023)
• Changes in Bone Quality after Treatment with Etelcalcetide (CJASN, 2023)
• The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism (Clinical Nephrology, 2025)